Viatris Aktie

8,23 EUR -0,15 EUR -1,77 %

27.03.2025

STU

8,84 USD -0,13 USD -1,45 %

27.03.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.9,91 Mrd. EUR

Div. Rendite3,86%

WKNA2QAME

ISINUS92556V1061

SymbolVTRS

Viatris Aktien News

Sortieren:Datum Meistgelesen

18.10.23PR NewswireViatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking

10.10.23PR NewswireViatris to Release Third Quarter 2023 Financial Results on November 7, 2023

03.10.23finanzen.netS&P 500-Entwicklung

Börse New York: So bewegt sich der S&P 500 nachmittags

03.10.23finanzen.netKursverlauf

Verluste in New York: S&P 500 gibt nach

03.10.23Dow JonesAbgewiesen

Novo Nordisk-Aktie profitiert marginal: Anfechtung von Novo-Nordisk-Patenten in den USA scheitert

03.10.23finanzen.netFeiertagshandel: DAX schließt tiefer -- US-Börsen letztlich verlustreich -- Eli Lilly will POINT übernehmen -- JPMorgan-Analyst wird pessimistischer für Tesla -- Ford, GM, RWE, E.ON im Fokus

02.10.23finanzen.netIndex-Performance im Fokus

Börse New York in Rot: S&P 500 schwächer

02.10.23finanzen.netS&P 500-Kursentwicklung

S&P 500-Handel aktuell: S&P 500 präsentiert sich mittags leichter

02.10.23finanzen.netS&P 500-Kursentwicklung

Minuszeichen in New York: S&P 500 fällt zum Handelsstart

01.10.23PR NewswireViatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA

27.09.23PR NewswireViatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Ago...

12.09.23PR NewswireViatris Named to TIME's World's Best Companies 2023 List

08.08.23MyDividendsViatris kündigt Dividende an

08.08.23finanzen.netViatris präsentierte Bilanzzahlen zum jüngsten Jahresviertel

07.08.23PR NewswireViatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

06.08.23finanzen.netAusblick: Viatris informiert über die jüngsten Quartalsergebnisse

31.07.23PR NewswireViatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstr...

23.07.23finanzen.netErste Schätzungen: Viatris legt die Bilanz zum abgelaufenen Quartal vor

13.07.23PR NewswireVTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

11.07.23PR NewswireVTRS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 14, 2023 in the Class Action Filed on Behalf of Viatris Inc. Shareholders

08.07.23PR NewswireVIATRIS DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options

07.07.23PR NewswireROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS

07.07.23PR NewswireVTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023

03.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS

01.07.23PR NewswireROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS

30.06.23PR NewswireVTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023

29.06.23PR NewswireVTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

28.06.23PR NewswireViatris to Report Second Quarter 2023 Financial Results on August 7, 2023

20.06.23PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

17.06.23PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Viatris, Inc. and Certain Officers - VTRS

09.06.23PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

06.06.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

01.06.23PR NewswireVIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Vi...

30.05.23PR NewswireKESSLER TOPAZ MELTZER & CHECK, LLP ANNOUNCES A SECURITIES FRAUD CLASS ACTION FILED AGAINST VIATRIS INC. (VTRS)

30.05.23PR NewswireViatris Named to USA Today's Inaugural List of America's Climate Leaders 2023

22.05.23PR NewswireInvestor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Viatris Inc. (VTRS) Investors of Class Action and to Actively Participate

22.05.23PR NewswireRobert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year

22.05.23PR NewswireViatris Announces Appointment of Leo Groothuis to Company's Board of Directors

19.05.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

18.05.23PR NewswireROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

Viatris News

Viatris News: auf dieser Seite finden Sie alle Viatris News und Nachrichten zur Viatris Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viatris News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viatris News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.